Vol 12, Supp. B (2021)
Case report
Published online: 2021-06-11

open access

Page views 310
Article views/downloads 266
Get Citation

Connect on Social Media

Connect on Social Media

Skirmishes with primary immune thrombocytopenia

Justyna Gil1

Abstract

The article presents a case report of a patient with refractory primary immune thrombocytopenia. Despite the use of steroid therapy, splenectomy followed by azathioprine and mycophenolate mofetil, safe platelet values were not achieved. Only the inclusion of eltrombopag in the treatment brought the desired effect. In October, the patient was infected with COVID-19. He required hospitalization due to pneumonia. Temporarily, as a result of systemic steroid therapy resulting in an increase in platelet values, the thrombopoietin agonist was discontinued. The patient left the Department of Infectious Diseases in a good condition and is now taking eltrombopag again.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Szczeklik A. ed. Choroby wewnętrzne. Tom II. Wydawnictwo Medycyna Praktyczna, Kraków 2005: 1558–1561.
  2. Puavilai T, Thadanipon K, Rattanasiri S, et al. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis. Br J Haematol. 2020; 188(3): 450–459.
  3. Bylsma LC, Fryzek J, Cetin K, et al. Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting. Am J Hematol. 2018; 94(1): 118–132.
  4. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017; 129(21): 2829–2835.
  5. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115(2): 168–186.
  6. Provan D. Characteristics of immune thrombocytopenic purpura: a guide for clinical practice. Eur J Haematol Suppl. 2009(71): 8–12.
  7. Nomura S. Advances in diagnosis and treatments for immune thrombocytopenia. Clin Med Insights Blood Disord. 2016; 9: 15–22.
  8. Cooper N. Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia. Hematol Oncol Clin North Am. 2009; 23(6): 1317–1327.
  9. Provan D, Newland AC. Current management of primary immune thrombocytopenia. Adv Ther. 2015; 32(10): 875–887.
  10. Fattizzo B, Levati G, Cassin R, et al. Eltrombopag in immune thrombocytopenia, aplastic anemia, and myelodysplastic syndrome: from megakaryopoiesis to immunomodulation. Drugs. 2019; 79(12): 1305–1319.
  11. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011; 377(9763): 393–402.
  12. Arnold DM, Heddle NM, Carruthers J, et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood. 2012; 119(6): 1356–1362.
  13. Cuker A, Cines DB, Neunert CE. Controversies in the treatment of immune thrombocytopenia. Curr Opin Hematol. 2016; 23(5): 479–485.
  14. Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for immune thrombocytopenia: down but not out. Blood. 2018; 131(11): 1172–1182.
  15. Pavord S, Thachil J, Hunt BJ, et al. Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol. 2020; 189(6): 1038–1043.



Hematology in Clinical Practice